Azacitidine Combined With Chidamide in the Treatment of Newly Diagnosed PTCL Unfit for Conventional Chemotherapy - Trial NCT04480125
Access comprehensive clinical trial information for NCT04480125 through Pure Global AI's free database. This Phase 2 trial is sponsored by Ruijin Hospital and is currently Recruiting. The study focuses on Peripheral T-cell Lymphoma. Target enrollment is 28 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Ruijin Hospital
Timeline & Enrollment
Phase 2
Jun 20, 2020
Jun 20, 2024
Primary Outcome
Complete response rate
Summary
This prospective, open-label, single-arm study will evaluate the efficacy and safety of
 azacitidine in combination with chidamide in treatment of newly diagnosed peripheral T-cell
 lymphoma unfit for conventional chemotherapy.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT04480125
Non-Device Trial